Payment overview · 2025
General Payments
$920.49
33 reported records · 17 companies
Healthcare provider profile · identity verified
Gregory Scott Carlson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · COACHELLA, CA · NPI 1740822576
Verified facts
What the public records show
CMS Open Payments records show Gregory Scott Carlson, NP received $920.49 in general payments during 2025 across 33 reported records.
Abbott Laboratories accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $165.72 | 18.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $129.20 | 14.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $100.81 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.43 | 8.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.59 | 8.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $67.06 | 7.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.03 | 6.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.17 | 5.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.35 | 3.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.86 | 3.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.56 | 3.4% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.44 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.29 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.28 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.46 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.24 | 1.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.00 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $920.49 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $165.72 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $129.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.81 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.43 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $67.06 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.79 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.03 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.17 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.35 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 193 | 86 |
| Prednisone | Prednisone | 170 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 45 |
| Azithromycin | Azithromycin | 109 | 93 |
| Gabapentin | Gabapentin | 109 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 107 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 41 |
| Ozempic | Semaglutide | 80 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 32 |
| Donepezil Hcl | Donepezil Hcl | 75 | 27 |
| Trazodone Hcl | Trazodone Hcl | 74 | 31 |
| Losartan Potassium | Losartan Potassium | 73 | 28 |
| Furosemide | Furosemide | 65 | 31 |
| Tramadol Hcl | Tramadol Hcl | 65 | 23 |
| Metformin Hcl Er | Metformin Hcl | 60 | 27 |
| Lisinopril | Lisinopril | 59 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Glimepiride | Glimepiride | 46 | 18 |
| Alprazolam | Alprazolam | 45 | 21 |
| Buspirone Hcl | Buspirone Hcl | 45 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | 21 |
| Metformin Hcl | Metformin Hcl | 40 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 20 |
| Potassium Chloride | Potassium Chloride | 39 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 18 |
| Naproxen | Naproxen | 37 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 26 |
| Allopurinol | Allopurinol | 34 | 11 |
| Omeprazole | Omeprazole | 33 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 15 |
| Ezetimibe | Ezetimibe | 29 | 13 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Carvedilol | Carvedilol | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $920.49 · 33 records | Abbott Laboratories | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, INTELLIS ADAPTIVESTIM, Korlym, Leqembi, MOUNJARO, OFEV, REPATHA, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error